The Gut Healing Stack — Larazotide, KPV, and BPC-157 Research Protocol
The Gut Healing Stack is the most comprehensive all-oral gut research protocol in the Peptide Hub database — combining Larazotide (AT-1001) for tight junction repair, KPV for mucosal anti-inflammatory signaling, and BPC-157 oral for GI tissue healing. Each compound addresses a distinct layer of gut pathology that the others do not cover, making the combination mechanistically additive across the spectrum of gut dysfunction research.
Three layers of gut pathology — three distinct mechanisms
Gut dysfunction in conditions like IBD, leaky gut, celiac disease, SIBO, and post-infectious gut damage typically involves three simultaneous pathological processes: structural barrier breakdown (disrupted tight junctions allowing luminal translocation), inflammatory mucosal immune overactivation (cytokine production driving ongoing tissue damage), and physical tissue injury (ulceration, mucosal erosion, fistula formation). Most gut interventions address one or two of these layers. The Gut Healing Stack addresses all three simultaneously through distinct mechanisms at each layer.
Layer 1 — Larazotide: restoring the tight junction structure
Larazotide (AT-1001) is the only clinically studied pharmaceutical peptide specifically designed to stabilize intestinal tight junctions. By binding the ZOT receptor on intestinal epithelial cells, Larazotide prevents disruption of the occludin and claudin tight junction proteins that seal the paracellular space between cells. This is the upstream structural intervention — without tight junction restoration, the inflammatory and tissue-damage processes are continuously fed by new luminal translocation events. Phase 2 human data in 342 celiac disease patients confirmed significant symptom reduction and improved barrier function at 0.5mg three times daily for 12 weeks. Administered 30 minutes before meals for maximum luminal residence during the highest-risk permeability period. See the Larazotide research profile.
Layer 2 — KPV: calming the mucosal immune response
With the barrier partially restored by Larazotide, KPV's melanocortin receptor-mediated anti-inflammatory signaling addresses the immune response to translocation that has already occurred. NF-kB suppression reduces the pro-inflammatory cytokine production (IL-6, TNF-alpha, IL-1beta) that drives mucosal damage in IBD and related conditions. KPV also promotes intestinal epithelial cell migration — accelerating the re-epithelialization process that physically closes mucosal gaps. Its oral or SubQ administration provides continuous anti-inflammatory signaling during the healing period. See the KPV database entry.
Layer 3 — BPC-157 oral: healing the tissue itself
BPC-157 in oral tablet form concentrates in the GI tract — its original isolation from gastric juice and its stability in gastric acid make oral administration the most targeted route for GI applications. VEGFR2-driven angiogenesis repairs the blood vessel supply to damaged mucosal tissue, ERK1/2 pathway activation drives fibroblast-mediated structural repair, and growth hormone receptor upregulation in gut fibroblasts amplifies the healing response. The 2025 American Journal of Gastroenterology review of 36 studies confirmed BPC-157's cytoprotective and pro-healing effects across ulceration, anastomotic repair, IBD, and NSAID-induced injury. Taken with meals for maximum GI contact time. See the BPC-157 Oral Tablets database entry.
Adding BT-11 for advanced IBD research protocols
For research specifically focused on IBD (Crohn's disease, ulcerative colitis), BT-11 can be added as a fourth component — its LANCL2 receptor-mediated local IL-10 signaling addresses the inflammatory pathway at a different receptor system than KPV's melanocortin mechanism, providing mechanistically additive anti-inflammatory coverage. BT-11 has the strongest human trial evidence of any novel gut inflammation research peptide, with Phase 2 data in both Crohn's and UC. The combined Larazotide + KPV + BPC-157 + BT-11 protocol represents the most comprehensive mechanistic coverage of IBD pathology available in the current database. See the BT-11 research profile. Also see the Gut-Brain Axis guide for the neurological context of gut barrier research.